Cargando…

Impact of Concomitant Aberrant CD200 and BCL2 Overexpression on Outcome of Acute Myeloid Leukemia: A Cohort Study from a Single Center

OBJECTIVE: CD200 and BCL2 overexpression is independently associated with inferior survival in acute myeloid leukemia (AML), and these two factors are frequently co-expressed; however, no data are available on the role of concomitant aberrant CD200 and BCL2 expression on outcome of AML patients. We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tiribelli, Mario, Michelutti, Angela, Cavallin, Margherita, Di Giusto, Sara, Fanin, Renato, Damiani, Daniela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8171206/ https://www.ncbi.nlm.nih.gov/pubmed/33596632 http://dx.doi.org/10.4274/tjh.galenos.2021.2020.0728

Ejemplares similares

BCL-2 Expression in AML Patients over 65 Years: Impact on Outcomes across Different Therapeutic Strategies
por: Tiribelli, Mario, et al.
Publicado: (2021)

Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors
por: Damiani, Daniela, et al.
Publicado: (2015)

Checkpoint Inhibitors in Acute Myeloid Leukemia
por: Damiani, Daniela, et al.
Publicado: (2023)

Present and Future Role of Immune Targets in Acute Myeloid Leukemia
por: Damiani, Daniela, et al.
Publicado: (2022)

ABCG2 in Acute Myeloid Leukemia: Old and New Perspectives
por: Damiani, Daniela, et al.
Publicado: (2023)

BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia
por: Zhou, Jing-dong, et al.
Publicado: (2019)

Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models
por: Han, Lina, et al.
Publicado: (2020)

Clinical Significance of CD200 and CD56 Expression in Patients with Acute Myeloid Leukemia
por: Aref, Salah, et al.
Publicado: (2020)

The serological prevalence of SARS‐CoV‐2 infection in patients with chronic myeloid leukemia is similar to that in the general population
por: Bonifacio, Massimiliano, et al.
Publicado: (2021)

Concomitant AID Expression and BCL7A Loss Associates With Accelerated Phase Progression and Imatinib Resistance in Chronic Myeloid Leukemia
por: Yu, Nae, et al.
Publicado: (2017)

Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
por: Wei, Yunxiong, et al.
Publicado: (2020)

PB1817: PROGNOSTIC SIGNIFICANCE OF CD200 ON ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA AND ITS MECHANISM
por: Quan, X., et al.
Publicado: (2022)

Serological Prevalence of Sars-Cov-2 Infection Among Chronic Myeloid Leukemia Patients Undergoing Tyrosine Kinase Inhibitor Treatment in Italy (COVID-19-HEM Study)
por: Bonifacio, Massimiliano, et al.
Publicado: (2020)

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
por: Tiribelli, Mario, et al.
Publicado: (2019)

Corrigendum: Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
por: Wei, Yunxiong, et al.
Publicado: (2020)

Aberrant CD200/CD200R1 expression contributes to painful synovium hyperplasia in a patient with primary hypertrophic osteoarthropathy
por: Ren, Yan, et al.
Publicado: (2013)

Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34(+ )acute myeloid leukemia cell lines and primary sorted CD34(+ )acute myeloid leukemia cells
por: Rao, Jia, et al.
Publicado: (2011)

Interaction of CD200 Overexpression on Tumor Cells with CD200R1 Overexpression on Stromal Cells: An Escape from the Host Immune Response in Rectal Cancer Patients
por: Bisgin, Atil, et al.
Publicado: (2019)

Editorial: Advances in the treatment of chronic myeloid leukemia
por: Eşkazan, Ahmet Emre, et al.
Publicado: (2023)

BCL7A is silenced by hypermethylation to promote acute myeloid leukemia
por: Patiño-Mercau, Juan Rodrigo, et al.
Publicado: (2023)

Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3(+) regulatory T cells
por: Coles, S J, et al.
Publicado: (2012)

Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy?
por: Kulsoom, Bibi, et al.
Publicado: (2018)

Derepression of retroelements in acute myeloid leukemia with 3q aberrations
por: Mika, Jagoda, et al.
Publicado: (2021)

Aberrant CD200/CD200R1 expression and function in systemic lupus erythematosus contributes to abnormal T-cell responsiveness and dendritic cell activity
por: Li, Yang, et al.
Publicado: (2012)

Acute Myeloid Leukemia with Concomitant BCR-ABL and NPM1 Mutations
por: Mariotti, Benedetta, et al.
Publicado: (2019)

CD200 and Chronic Lymphocytic Leukemia: Biological and Clinical Relevance
por: D’Arena, Giovanni, et al.
Publicado: (2020)

Prognostic Role of CD200 in Acute Lymphoblastic Leukemia Patients
por: Khalil, Mohamed, et al.
Publicado: (2023)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
por: Xu, Xi, et al.
Publicado: (2023)

Aberrant Methylation of APAF-1 Gene in Acute Myeloid Leukemia Patients
por: Rostami, Shahrbano, et al.
Publicado: (2017)

Aberrant DNA Methylation in Acute Myeloid Leukemia and Its Clinical Implications
por: Yang, Xianwen, et al.
Publicado: (2019)

Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations
por: Dutta, Sayantanee, et al.
Publicado: (2022)

CD200 Baseline Serum Levels Predict Prognosis of Chronic Lymphocytic Leukemia
por: D’Arena, Giovanni, et al.
Publicado: (2021)

MiR-130a is aberrantly overexpressed in adult acute myeloid leukemia with t(8;21) and its suppression induces AML cell death
por: Ding, Chao, et al.
Publicado: (2018)

Dysregulation of miR-200s clusters as potential prognostic biomarkers in acute myeloid leukemia
por: Zhou, Jing-dong, et al.
Publicado: (2018)

225Ac‐labeled CD33‐targeting antibody reverses resistance to Bcl‐2 inhibitor venetoclax in acute myeloid leukemia models
por: Garg, Ravendra, et al.
Publicado: (2020)

Prognostic Value of Serum CD200 Concentrations in Chronic Lymphocytic Leukemia
por: Aref, Salah, et al.
Publicado: (2023)

Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML
por: Herbrich, Shelley, et al.
Publicado: (2021)

Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia
por: Brinton, Lindsey T., et al.
Publicado: (2020)

Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia
por: Wei, Wenwen, et al.
Publicado: (2022)

BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia
por: Hurtz, Christian, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_p0os41leo63c2h9usqhbrqqlvf